Sigyn Therapeutics, Inc. logo

Sigyn Therapeutics, Inc.

0001642159

Sigyn Therapeutics is developing dialysis-like therapies to address cardiovascular disease and cancer. Their therapies aim to improve patient lives. Key products/services include CardioDialysis™ for cardiovascular disease and ImmunePrep™, ChemoPrep™, and ChemoPure™ for cancer treatment. The company aims to provide strategic value to the dialysis and biopharmaceutical industry.

80
Meget Pålitelig
Tillitsscore

Offisielt Register

Foretaksnavn
Sigyn Therapeutics, Inc.
Organisasjonsnummer
0001642159
MVA Nummer
472573116
Firmastatus
Active
Adresse
9190 W OLYMPIC BLVD # 263, BEVERLY HILLS, CA 90212
Bransjekoder
3841: Surgical & Medical Instruments & Apparatus

Sist verifisert: 1/2/2026

AI Kvalitetsanalyse

Bransje
Biotechnology
SSL/HTTPS
Sikker
Profesjonell E-post
Ja
Kontakt E-post
info@vstocktransfer.com

🌟 Lignende Pålitelige Bedrifter

Context Therapeutics Inc.

Context Therapeutics Inc. logo
86/100 · Meget Pålitelig

Context Therapeutics is dedicated to advancing the treatment of solid tumors through the development of next-generation T cell engaging (TCE) bispecific antibody therapies. Their innovative pipeline features clinical-stage bispecific therapeutics designed to harness the immune system for targeted cancer eradication. The company focuses on innovative immunotherapeutic solutions, transforming cancer care and improving outcomes for patients.

2001 MARKET STREET, USA
Se profil

AGENUS INC

AGENUS INC logo
86/100 · Meget Pålitelig

Agenus is a biotechnology company focused on developing and commercializing immuno-oncology therapies. Their key products include botensilimab and balstilimab, which are in clinical trials for various cancers. The company is positioned as an innovator in the development of next-generation immunotherapies.

3 FORBES ROAD, USA
Se profil

Evaxion A/S

Evaxion A/S logo
77/100 · Pålitelig

Evaxion utilizes its AI-Immunology™ platform to challenge and improve standardized treatments. In oncology, they create personalized therapies, tailoring treatment to the individual. For infectious diseases, they design next-generation vaccines to address unmet medical needs. Their AI platform accelerates vaccine target discovery, design, and development.

DR NEERGAARDS VEJ 5F, USA
Se profil